#WCLC23 Update from the TRIDENT-1 trial on repotrectinib in #ROS1 NSCLC from Dr. Byoung Chul Cho. Multi-cohort study in ROS1 and NTRK tumors but this update is on TKI-naive and post one TKI (chemo naive) cohorts.
Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. https://t.co/iNeyYviX4U
Congratulations to Dr. Dan Von Hoff. His exceptional contributions also include the advice on cancer research and clinical trails for biotech companies.
I am delighted that the @AACR has established this award to honor Dan Von Hoff’s exceptional contributions to the training of cancer investigators. https://t.co/PLglyNQsKL /1
U.S. COVID update: Daily death toll at highest level since May, number in hospital rises 5% in one day
- New cases: 144,270
- Positivity rate: 10.4% (-0.2)
- In hospital: 65,368 (+3,404)
- In ICU: 12,518 (+566)
- New deaths: 1,562
- Data: COVID Tracking Project
Only a big company like $PFE has the resources to invest $2 BILLION at risk for a truly novel vaccine. Perhaps people will now appreciate Big Pharma a bit more.
November is lung cancer awareness month. Visit the TOGA website to learn more about lung cancer and hear a podcast from where I get to chat with my very talented friend @TommyJohn00 https://t.co/R9DrLJdlKc #LCSM
We recognize that the presentation of new data, exchange of information, and opportunities for collaboration offered during the Annual Meeting are invaluable, and we are working actively to develop an interactive and comprehensive virtual meeting.
#AACR21
Covid hospitalizations, a critical and objective measure of disease burden in the U.S., are starting to accelerate; reaching nearly 42,000 today. Criteria for admission has been tightened over time, making the high numbers more concerning. Deaths, which lag, are also rising.